18-Jun-2026
Assembly Biosciences Announces Upcoming Investor Conference Presentations
Globe Newswire (Thu, 28-May 4:05 PM ET)
Globe Newswire (Tue, 26-May 4:05 PM ET)
Globe Newswire (Fri, 22-May 7:05 AM ET)
Globe Newswire (Fri, 22-May 7:00 AM ET)
Globe Newswire (Wed, 13-May 2:00 AM ET)
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
Globe Newswire (Mon, 11-May 8:00 AM ET)
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Globe Newswire (Thu, 7-May 4:00 PM ET)
Globe Newswire (Thu, 9-Apr 8:00 AM ET)
Market Chameleon (Fri, 20-Mar 5:59 AM ET)
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Assembly Biosciences trades on the NASDAQ stock market under the symbol ASMB.
As of June 18, 2026, ASMB stock price climbed to $24.44 with 292,058 million shares trading.
ASMB has a beta of 0.77, meaning it tends to be less sensitive to market movements. ASMB has a correlation of 0.03 to the broad based SPY ETF.
ASMB has a market cap of $484.33 million. This is considered a Small Cap stock.
Last quarter Assembly Biosciences reported $8 million in Revenue and -$.54 earnings per share. This beat revenue expectation by $813,600 and exceeded earnings estimates by $.12.
In the last 3 years, ASMB traded as high as $39.71 and as low as $7.69.
The top ETF exchange traded funds that ASMB belongs to (by Net Assets): VTI, VXF, VHT, IWC, BBC.
ASMB has outperformed the market in the last year with a price return of +42.6% while the SPY ETF gained +26.9%. However, in the short term, ASMB had mixed performance relative to the market. It has underperformed in the last 3 months, returning -11.2% vs +13.5% return in SPY. But in the last 2 weeks, ASMB shares have fared better than the market returning +1.4% compared to SPY -1.1%.
ASMB support price is $23.05 and resistance is $25.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASMB shares will trade within this expected range on the day.